An Efficient End-To-End AAV8 Platform Process At 50 L Scale Using Sartorius Technology

As adeno-associated virus (AAV) vectors continue to gain traction in advanced therapies, manufacturers face persistent challenges in scaling production, improving recovery rates, and separating full from empty capsids. This application note introduces a comprehensive AAV production platform built entirely on Sartorius technologies, spanning upstream and downstream processes. HEK293 cells were expanded from a 10 L rocking bioreactor to a 50 L stirred-tank reactor, followed by a downstream workflow that included filtration, tangential flow filtration, and serotype-independent chromatography. The platform delivered a 23% recovery of viral genomes and significantly improved product quality, boosting full capsid content from 21% to 68%. Host cell DNA was reduced by 98.5%, and host cell protein was eliminated to non-detectable levels.

For teams seeking scalable, high-purity AAV production, learn more about a detailed and practical solution.